Recent investigations have converged on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopamine communication. While GIP stimulators are commonly employed for addressing type 2 T2DM, their potential effects on reinforcement ci